Viewing Study NCT00907205

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:25 AM
Ignite Modification Date: 2026-01-07 @ 12:45 PM
Study NCT ID: NCT00907205
Status: COMPLETED
Last Update Posted: 2013-06-13
First Post: 2009-05-20
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
Sponsor: Semafore Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced or Metastatic Solid Tumors View
None Cancer View
None Solid Cancers View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Advanced Solid Tumors View
None Metastatic Solid Tumors View
None PI3K View
None PI3K Inhibitors View
None PI3 Kinase Inhibitors View
None mTORC inhibitor View
None mTORC1 inhibitor View
None mTORC2 inhibitor View
None vascular targeted View
None conjugate View